Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Mahajan, 2021 RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
41/41 inconclusive
    SOLIDARITY (remdesivir), 2020
     
    NCT04315948
    RCTremdesivirstandard of careCOVID 19 hospitalizedsome concern
    2750/2725 inconclusive
    • inconclusive 5 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID 19 all comers meta-analysis

    NIH NIAID ACTT-1, 2020
     
    NCT04280705
    RCTremdesivirplaceboCOVID 19 all comerssome concern
    541/521 suggested
    • suggested 45 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 29 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 35 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 mild to moderate meta-analysis

    GS-US-540-5774, 10 days, 2020
     
    NCT04292730
    RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
    197/200 safety concern
    • suggested 58 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 88 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 63 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
    The primary endpoint was not met, no odds ratio is reported because the proportional odds assumption was not met
    GS-US-540-5774, 5 days, 2020
     
    NCT04292730
    RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
    199/200 conclusif
    • demonstrated 65 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 severe or critically meta-analysis

    CAP-China (Wang et al.), 2020
     
    NCT04257656
    RCTremdesivirplaceboCOVID-19 severe or criticallylow
    158/79 inconclusive
    • inconclusive 23 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a high degree of certainty due to low risk of bias
    2 studies excluded by filtering options (2 RCT / 0 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).